Kinase-independent role for CRAF-driving tumour radioresistance via CHK2

Nature Communications

Volumn 6, Issue , 2015, Pages

  Advani, Sunil J ^a   Camargo, Maria Fernanda ^b   Seguin, Laetitia ^b   Mielgo, Ainhoa ^b   Anand, Sudarshan ^b   Hicks, Angel M ^a   Aguilera, Joseph ^a   Franovic, Aleksandra ^b   Weis, Sara M ^b   Cheresh, David A ^b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT KINASE 2; CRAF KINASE; ETOPOSIDE; MUTANT PROTEIN; P21 ACTIVATED KINASE 1; P21 ACTIVATED KINASE 2; PHOSPHOTRANSFERASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; B RAF KINASE; BRAF PROTEIN, HUMAN; CHEK2 PROTEIN, HUMAN; P21 ACTIVATED KINASE; PAK1 PROTEIN, HUMAN; RAF PROTEIN; SERINE;

CELLS AND CELL COMPONENTS; DRUG; ENZYME ACTIVITY; GENE EXPRESSION; GENOTOXICITY; INHIBITOR; METABOLISM; MUTATION; PROTEIN; TUMOR;

ALLOSTERISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CYCLE PROGRESSION; CELL MOTILITY; CELL SURVIVAL; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; ENZYME PHOSPHORYLATION; FEMALE; GENE SILENCING; HCT116 CELL LINE; HUMAN; HUMAN CELL; IONIZING RADIATION; MOUSE; NONHUMAN; RADIATION DOSE; RADIATION PROTECTION; RADIOSENSITIVITY; RADIOSENSITIZATION; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; DRUG SCREENING; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; HCT 116 CELL LINE; IMMUNOBLOTTING; IMMUNOPRECIPITATION; METABOLISM; MUTATION; PHOSPHORYLATION; RADIATION RESPONSE; RADIATION TOLERANCE; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CHECKPOINT KINASE 2; DNA DAMAGE; FLUORESCENT ANTIBODY TECHNIQUE; HCT116 CELLS; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MICE; MUTATION; NEOPLASM TRANSPLANTATION; P21-ACTIVATED KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RAF; RADIATION TOLERANCE; RADIATION, IONIZING; SERINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84940901464     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms9154     Document Type: Article

References (40)

1. Seguin, L. et al. An integrin beta3-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat. Cell Biol. 16, 457-468 (2014).
2. Pao, W. et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2, e17 (2005).
3. Nazarian, R. et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973-977 (2010).
4. Wilson, T. R. et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487, 505-509 (2012).
5. McKenna, W. G., Muschel, R. J., Gupta, A. K., Hahn, S. M. & Bernhard, E. J. The RAS signal transduction pathway and its role in radiation sensitivity. Oncogene 22, 5866-5875 (2003).
6. Rengan, R., Cengel, K. A. & Hahn, S. M. Clinical target promiscuity: lessons from ras molecular trials. Cancer Metast. Rev. 27, 403-414 (2008).
7. Kasid, U. et al. Activation of Raf by ionizing radiation. Nature 382, 813-816 (1996).
8. Kasid, U. et al. Effect of antisense c-raf-1 on tumorigenicity and radiation sensitivity of a human squamous carcinoma. Science 243, 1354-1356 (1989).
9. Dritschilo, A. et al. Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies. Clin. Cancer Res. 12, 1251-1259 (2006).
10. Dai, X. F. et al. Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway. Int. J. Radiat. Biol. 89, 724-731 (2013).
11. Wild, A. T. et al. Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma. PLoS ONE 8, e65726 (2013).
12. Plastaras, J. P. et al. Cell cycle-dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res. 67, 9443-9454 (2007).
13. Bonner, J. A., Vroman, B. T., Christianson, T. J. & Karnitz, L. M. Ionizing radiation-induced MEK and Erk activation does not enhance survival of irradiated human squamous carcinoma cells. Int. J. Radiat. Oncol. Biol. Phys. 42, 921-925 (1998).
14. Grana, T. M., Rusyn, E. V., Zhou, H., Sartor, C. I. & Cox, A. D. Ras mediates radioresistance through both phosphatidylinositol 3-kinase-dependent and Raf-dependent but mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-independent signaling pathways. Cancer Res. 62, 4142-4150 (2002).
15. Matallanas, D. et al. Raf Family Kinases. Genes Cancer 2, 232-260 (2011).
16. Alavi, A. S., Acevedo, L., Min, W. & Cheresh, D. A. Chemoresistance of endothelial cells induced by basic fibroblast growth factor depends on Raf-1-mediated inhibition of the proapoptotic kinase, ASK1. Cancer Res. 67, 2766-2772 (2007).
17. O'Neill, E., Rushworth, L., Baccarini, M. & Kolch, W. Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1. Science 306, 2267-2270 (2004).
18. Ehrenreiter, K. et al. Raf-1 regulates Rho signaling and cell migration. J. Cell Biol. 168, 955-964 (2005).
19. Mielgo, A. et al. A MEK-independent role for CRAF in mitosis and tumor progression. Nat. Med. 17, 1641-1645 (2011).
20. Murphy, E. A. et al. Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRb/B-RAF. Proc. Natl Acad. Sci. USA 107, 4299-4304 (2010).
21. Sancar, A., Lindsey-Boltz, L. A., Unsal-Kacmaz, K. & Linn, S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu. Rev. Biochem. 73, 39-85 (2004).
22. Jin, S., Zhuo, Y., Guo, W. & Field, J. p21-activated kinase 1 (Pak1)-dependent phosphorylation of Raf-1 regulates its mitochondrial localization, phosphorylation of BAD, and Bcl-2 association. J. Biol. Chem. 280, 24698-24705 (2005).
23. King, A. J. et al. The protein kinase Pak3 positively regulates Raf-1 activity through phosphorylation of serine 338. Nature 396, 180-183 (1998).
24. Wu, X., Carr, H. S., Dan, I., Ruvolo, P. P. & Frost, J. A. p21 activated kinase 5 activates Raf-1 and targets it to mitochondria. J. Cell. Biochem. 105, 167-175 (2008).
25. Zang, M., Hayne, C. & Luo, Z. Interaction between active Pak1 and Raf-1 Is necessary for phosphorylation and activation of Raf-1. J. Biol. Chem. 277, 4395-4405 (2002).
26. Khanna, K. K. & Jackson, S. P. DNA double-strand breaks: signaling, repair and the cancer connection. Nat. Genet. 27, 247-254 (2001).
27. Snyder, A. R. & Morgan, W. F. Gene expression profiling after irradiation: clues to understanding acute and persistent responses? Cancer Metast. Rev. 23, 259-268 (2004).
28. Smith, J., Tho, L. M., Xu, N. & Gillespie, D. A. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv. Cancer Res. 108, 73-112 (2010).
29. Choudhury, A., Cuddihy, A. & Bristow, R. G. Radiation and new molecular agents part I: targeting ATM-ATR checkpoints, DNA repair, and the proteasome. Semin. Radiat. Oncol. 16, 51-58 (2006).
30. Bao, S. et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756-760 (2006).
31. Jobson, A. G. et al. Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]. J. Pharmacol. Exp. Ther. 331, 816-826 (2009).
32. Wang, W. J. et al. MYC regulation of CHK1 and CHK2 promotes radioresistance in a stem cell-like population of nasopharyngeal carcinoma cells. Cancer Res. 73, 1219-1231 (2013).
33. Yu, Q., Rose, J. H., Zhang, H. & Pommier, Y. Antisense inhibition of Chk2/hCds1 expression attenuates DNA damage-induced S and G2 checkpoints and enhances apoptotic activity in HEK-293 cells. FEBS Lett. 505, 7-12 (2001).
34. McGlynn, L. M. et al. Ras/Raf-1/MAPK pathway mediates response to tamoxifen but not chemotherapy in breast cancer patients. Clin. Cancer Res. 15, 1487-1495 (2009).
35. Motwani, M., Li, D. Q., Horvath, A. & Kumar, R. Identification of novel gene targets and functions of p21-activated kinase 1 during DNA damage by gene expression profiling. PLoS ONE 8, e66585 (2013).
36. Ong, C. C. et al. Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. Proc. Natl Acad. Sci. USA 108, 7177-7182 (2011).
37. Kumar, R., Gururaj, A. E. & Barnes, C. J. p21-activated kinases in cancer. Nat. Rev. Cancer 6, 459-471 (2006).
38. Hatzivassiliou, G. et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431-435 (2010).
39. Heidorn, S. J. et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209-221 (2010).
40. Holderfield, M. et al. RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation. Cancer Cell 23, 594-602 (2013).